Exelixis, Inc. (NASDAQ:EXEL), a biopharmaceutical company with a market capitalization of $9.4 billion focused on developing and commercializing novel therapies for cancer treatment, stands at a ...
Hosted on MSN3m
Apellis Pharmaceuticals officer sells shares for $10,776Looking forward, Apellis is preparing for a supplemental new drug application (sNDA) for EMPAVELI® for the treatment of rare kidney diseases, with a U.S. launch anticipated in the second half of 2025 ...
In 2024, the Summers Value Fund LP (“the Fund”) delivered a net1 return of 27.4%. Click here to read the full letter.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback